Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2151 - 2175 of 15136 in total
Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl...
Approved
Investigational
Matched Description: … treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from ... known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and ... vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of thalidomide and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with...
Approved
Matched Description: … and toxicities. ... exists as a racemic mixture of the active S(-) and R(+) forms. ... [A228708] However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Approved
Investigational
Nutraceutical
Matched Iupac: … (2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid
Matched Description: … for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and
Matched Categories: … Amino Acids, Peptides, and Proteins …
NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by...
Approved
Nutraceutical
Matched Iupac: … [(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid
Matched Description: … electron carrier by being alternately oxidized (NAD+) and reduced (NADH). ... It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an ... NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide …
Matched Categories: … Enzymes and Coenzymes ... Nucleic Acids, Nucleotides, and Nucleosides …
Brivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.
Approved
Investigational
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Erdosteine is a drug that causes a breakdown of mucus, also known as a mucolytic agent. It is a thiol derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis. This drug contains sulfhydryl groups which are released after erdosteine undergoes hepatic...
Approved
Investigational
Matched Iupac: … 2-({[(2-oxothiolan-3-yl)carbamoyl]methyl}sulfanyl)acetic acid
Matched Description: … and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol ... Erdosteine 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly ... Erdosteine has been shown to be safe and well tolerated in clinical trials. …
Matched Categories: … Cough and Cold Preparations …
Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over...
Approved
Investigational
Matched Description: … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Chondroitinases and Chondroitin Lyases …
Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Approved
Matched Iupac: … (2S)-2-amino-4-[methyl(⁷⁵Se)selanyl]butanoic acid
Matched Categories: … Amino Acids, Peptides, and Proteins …
Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia....
Approved
Investigational
Matched Description: … Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and ... [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Approved
Matched Description: … It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Description: … An alkylating agent of value against both hematologic malignancies and solid tumors. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal...
Approved
Investigational
Matched Description: … Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. ... this same formulation gained additional approval in both the US and Canada in 2019 for the treatment ... a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients...
Approved
Matched Description: … People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues ... Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet ... metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced Parkinson's Disease).
Approved
Investigational
Matched Iupac: … (2S)-2-amino-3-[3-hydroxy-4-(phosphonooxy)phenyl]propanoic acid
Matched Description: … Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and
Matched Categories: … Dopa and Dopa Derivatives ... foslevodopa and decarboxylase inhibitor …
Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Approved
Withdrawn
Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management...
Approved
Investigational
Matched Description: … disease and end-of-dose motor fluctuations. ... Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase ... Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020 …
Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional group. Xylose is a sugar isolated from wood. D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. Xylose has also been used as a diagnostic agent to observe...
Approved
Matched Description: … D-Xylose is a sugar widely used as a diabetic sweetener in food and beverage. ... Xylose is a monosaccharide of the aldopentose type consisted of five carbon atoms and an aldehyde functional ... immediately - but its metabolism results in a variety of substrates that can serve important nutritional and
Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir[L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy.[A235725,A235735] Due to its...
Approved
Investigational
Matched Iupac: … -oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid
Matched Description: … analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and ... treatment of cytomegalovirus (CMV), BK Virus (BKV), adenoviruses (AdV), and Epstein-Barr virus (EBV) ... against several DNA viruses,[A235725] resulting in brincidofovir being investigated for the prevention and
Matched Categories: … Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha . Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic...
Approved
Investigational
Matched Description: … produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and ... Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the ... been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists ... Estrogens, Antiestrogens, and Estrogen Agonist-Antagonists …
Diethyltoluamide (DEET) is the common active ingredient in many insect repellent products. It is widely used to repel biting pests such as mosquitoes and ticks. Every year, DEET formulations are used to protect populations from mosquito-borne illnesses like West Nile Virus, the Zika virus, malaria, and/or tick-borne illnesses like Lyme...
Approved
Matched Description: … It is widely used to repel biting pests such as mosquitoes and ticks. ... /or tick-borne illnesses like Lyme disease and Rocky Mountain spotted fever. ... to protect populations from mosquito-borne illnesses like West Nile Virus, the Zika virus, malaria, and
Matched Categories: … Insecticides and Repellents ... Benzamides and benzamide derivatives ... Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Displaying drugs 2151 - 2175 of 15136 in total